Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Girish S Naik"'
Autor:
Sujith J Chandy, Girish S Naik, Reni Charles, Visalakshi Jeyaseelan, Elena N Naumova, Kurien Thomas, Cecilia Stalsby Lundborg
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e92206 (2014)
Antibiotic pressure contributes to rising antibiotic resistance. Policy guidelines encourage rational prescribing behavior, but effectiveness in containing antibiotic use needs further assessment. This study therefore assessed the patterns of antibio
Externí odkaz:
https://doaj.org/article/6a3629dc2afa4bb4aac30a766dce83f3
Autor:
Wenjun Zhong, Jiemin Ma, Cai Chen, E. J. Dettman, Razvan Cristescu, Girish S. Naik, Fan Jin, Changxia Shao
Publikováno v:
Cancer Medicine, Vol 13, Iss 11, Pp n/a-n/a (2024)
Abstract Introduction Hypoxia‐inducible factor‐2α (HIF‐2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC, SDHD, FH, and VHL genes) that are suspected to activate HIF‐2α are poo
Externí odkaz:
https://doaj.org/article/14ee2e820ebe4853b332cc7eed3202c1
Autor:
Jason J. Luke, Jedd D. Wolchok, Taha Merghoub, Cynthia A. Sirard, Diane Piper, Lianna Sifferlen, Phillip Wong, Aliya Holland, Jingjing Qi, Walter Newman, Olivier Rixe, David Bajor, Todd Bauer, Takami Sato, Girish S. Naik, Hong Wang, Roberta Zappasodi, Diwakar Davar
Supplementary Table from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06e8274a662db94b0372cb7e7542e809
https://doi.org/10.1158/1078-0432.22486856
https://doi.org/10.1158/1078-0432.22486856
Autor:
Jason J. Luke, Jedd D. Wolchok, Taha Merghoub, Cynthia A. Sirard, Diane Piper, Lianna Sifferlen, Phillip Wong, Aliya Holland, Jingjing Qi, Walter Newman, Olivier Rixe, David Bajor, Todd Bauer, Takami Sato, Girish S. Naik, Hong Wang, Roberta Zappasodi, Diwakar Davar
Purpose:TRX518 is a mAb engaging the glucocorticoid-induced TNF receptor−related protein (GITR). This open-label, phase I study (TRX518-003) evaluated the safety and efficacy of repeated dose TRX518 monotherapy and in combination with gemcitabine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d505d5d9e72ee2c945357f5aef741ec3
https://doi.org/10.1158/1078-0432.c.6532406.v1
https://doi.org/10.1158/1078-0432.c.6532406.v1
Autor:
Jason J. Luke, Jedd D. Wolchok, Taha Merghoub, Cynthia A. Sirard, Diane Piper, Lianna Sifferlen, Phillip Wong, Aliya Holland, Jingjing Qi, Walter Newman, Olivier Rixe, David Bajor, Todd Bauer, Takami Sato, Girish S. Naik, Hong Wang, Roberta Zappasodi, Diwakar Davar
Supplementary Data from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b804d37d72c5b64ee02158bbc8605da
https://doi.org/10.1158/1078-0432.22486880
https://doi.org/10.1158/1078-0432.22486880
Autor:
Jason J. Luke, Jedd D. Wolchok, Taha Merghoub, Cynthia A. Sirard, Diane Piper, Lianna Sifferlen, Phillip Wong, Aliya Holland, Jingjing Qi, Walter Newman, Olivier Rixe, David Bajor, Todd Bauer, Takami Sato, Girish S. Naik, Hong Wang, Roberta Zappasodi, Diwakar Davar
Supplementary Figure from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3addefab290e824d920fb0999caa57c8
https://doi.org/10.1158/1078-0432.22486877
https://doi.org/10.1158/1078-0432.22486877
Autor:
John H. Strickler, Johanna C. Bendell, Samuel J. Klempner, James B. Rottman, Michael H. Kagey, Stacey Stein, Girish S. Naik, Marya F. Chaney, Victoria M. Villaflor, Laura LaNiel Tenner, Cynthia A. Sirard
Publikováno v:
Molecular Cancer Therapeutics. 20:2240-2249
Therapeutic combinations targeting innate and adaptive immunity and predictive biomarkers of response in esophagogastric cancer (EGC) are needed. We assessed safety and clinical utility of DKN-01 (a novel DKK1-neutralizing IgG4 antibody) combined wit
Autor:
Diwakar Davar, Roberta Zappasodi, Hong Wang, Girish S. Naik, Takami Sato, Todd Bauer, David Bajor, Olivier Rixe, Walter Newman, Jingjing Qi, Aliya Holland, Phillip Wong, Lianna Sifferlen, Diane Piper, Cynthia A. Sirard, Taha Merghoub, Jedd D. Wolchok, Jason J. Luke
Publikováno v:
Clin Cancer Res
Purpose: TRX518 is a mAb engaging the glucocorticoid-induced TNF receptor−related protein (GITR). This open-label, phase I study (TRX518-003) evaluated the safety and efficacy of repeated dose TRX518 monotherapy and in combination with gemcitabine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60473b0d4d51a50755b6880e00e30770
https://europepmc.org/articles/PMC9475244/
https://europepmc.org/articles/PMC9475244/
Autor:
Patrick A. Ott, Rizwan Haq, Sushrut S. Waikar, F. Stephen Hodi, Girish S. Naik, Alistair E. W. Johnson, Elizabeth I. Buchbinder, Jonathan D. Schoenfeld
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-17 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background A male gender driven obesity paradox (improved survival for overweight/obese patients compared to normal weight) was recently shown in melanoma in the context of checkpoint inhibition (anti-PD-1/anti-CTLA4 monotherapy) in a pooled meta-ana
Autor:
Scott J. Rodig, Girish S. Naik, Evisa Gjini, Arpit Panda, Kevin Bi, Seth Maleri, Gabriel K. Griffin, W. Nicholas Haining, Martin W. LaFleur, Sarah A. Weiss, Margaret D. Zimmer, Kristen Felt, Robert T. Manguso, Arlene H. Sharpe, F. Stephen Hodi, Yamini V. Virkud, Jeffrey J. Ishizuka, Jenna L. Collier, Ana Lako, Debattama R. Sen, Juhi R. Kuchroo, Michael Manos, Rose Al Abosy, Brian C. Miller, Kathleen B. Yates, Flavian D. Brown, Dawn E. Comstock
Publikováno v:
Nat Immunol
T cell dysfunction is a hallmark of many cancers, but the basis for T cell dysfunction and the mechanisms by which antibody blockade of the inhibitory receptor PD-1 (anti-PD-1) reinvigorates T cells are not fully understood. Here we show that such th